KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma […]
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people […]
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company” or “Greenwich”), a clinical-stage biopharmaceutical […]